SecBot SecBot
PRESS-RELEASE ·Filed Aug 12, 2026

SPRO

Spero Therapeutics, Inc.
NEUTRAL
Impact 4/10
Horizonmonths Processed3mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight • Neutral

As a clinical-stage biotech with no revenue, the key catalysts are pipeline milestones and regulatory updates. Monitor for upcoming data readouts or partnership announcements, as these are the primary drivers for the stock. The current cash position provides a runway into 2027, reducing near-term financing risk.

DirectionNeutral
Confidencemedium
Horizonmonths

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$1.24
T+0 close · Aug 12, 2026 · via day close
Latest settled
−16.94%
T+60 · $1.03
Vs SPY
−11.46%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 13 $1.24entry
  2. T+1 · 3mo ago −0.81%α −0.61% · $1.23
  3. T+5 · 3mo ago −1.61%α +0.35% · $1.22
  4. T+20 · 2mo ago −8.87%α −7.12% · $1.13
  5. T+60 · 11d ago −16.94%α −11.46% · $1.03
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Spero Therapeutics reported Q2 2026 financial results, highlighting a net loss of $11.0 million for the quarter, compared to a net loss of $10.7 million in the same period last year. The company ended the quarter with $60.7 million in cash, cash equivalents, and marketable securities, providing a runway into 2027. The results are largely neutral for a clinical-stage biotech with no approved products, as the focus remains on pipeline development rather than financial performance.

Key Financial Metrics

EPS
−$0.13
Revenue
$0.00
est $0.00
Rating
in line

Key Facts

  • Net loss of $11.0 million for Q2 2026, compared to $10.7 million in Q2 2025.
  • Cash, cash equivalents, and marketable securities of $60.7 million as of June 30, 2026.
  • Research and development expenses were $7.5 million for Q2 2026, down from $8.5 million in Q2 2025.
  • General and administrative expenses were $4.2 million for Q2 2026, compared to $4.0 million in Q2 2025.
  • No revenue was reported for the quarter, consistent with the company's clinical-stage status.

Financial Impact

Net loss of $11.0 million, with cash runway into 2027.

net losscash positionr&d expenses

Risk Factors

  • Clinical trial failures or delays could significantly impact the stock.
  • Need for future capital raises to fund operations beyond current cash runway.
  • No approved products or revenue streams, making the company entirely dependent on pipeline success.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
0% bullish (6 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3344036

Track record

17 reports on SPRO

Performance horizon

4 of 8 bullish or bearish reports moved the stock their way by T+5. Best: +14.59% at T+20 after the Mar 26, 2026 report. 5 of 8 went positive at some point.

Filters
  1. Nov 12, 20264d ago 8-K Neutral 4/10 Entry $0.9999 Now $0.9460 −5.39% settles Nov 20
  2. Nov 10, 20266d ago 3 Neutral 2/10 Entry $1.02 Now $0.9460 −7.25% settles Nov 18
  3. Nov 10, 20266d ago 8-K Neutral 2/10 Entry $1.02 Now $0.9460 −7.25% settles Nov 18
  4. Oct 27, 202620d ago 8-K Neutral 2/10 Entry $1.17 to $1.07 Now $0.9460 −19.15% ▼ −8.55% −7.83% vs SPY
  5. Sep 11, 20269w ago EFFECT Bearish 7/10 Entry $1.13 to $1.13 Now $0.9460 +16.28% · 0.00% −0.34% vs SPY
  6. Aug 28, 202611w ago 8-K Bearish 7/10 Entry $1.22 to $1.19 Now $0.9460 +22.46% ▲ +2.46% +2.32% vs SPY
  7. Aug 28, 202611w ago S-3 Bearish 7/10 Entry $1.22 to $1.19 Now $0.9460 +22.46% ▲ +2.46% +2.32% vs SPY
  8. Aug 12, 202613w ago Press Release Neutral 4/10 Viewing Entry $1.24 to $1.22 Now $0.9460 −23.71% ▼ −1.61% +0.35% vs SPY
  9. Jul 14, 202617w ago 8-K Bullish 8/10 Entry $1.70 to $1.44 Now $0.9460 −44.35% ▼ −15.29% −14.00% vs SPY
  10. Jul 14, 202617w ago Press Release Bullish 7/10 Entry $1.70 to $1.44 Now $0.9460 −44.35% ▼ −15.29% −14.00% vs SPY
Showing 10 of 17

US Market Status

Market Closed · Opens Wed (10h 26m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 12, 2026